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There is a need to develop early biomarkers of acute kidney
injury following cardiac surgery, where morbidity and
mortality are increased by its presence. Plasma cystatin C
(CyC) and plasma and urine Neutrophil Gelatinase Associated
Lipocalin (NGAL) have been shown to detect kidney injury
earlier than changes in plasma creatinine in critically ill
patients. In order to determine the utility of urinary CyC
levels as a measure of kidney injury, we prospectively
collected plasma and urine from 72 adults undergoing
elective cardiac surgery for analysis. Acute kidney injury was
defined as a 25% or greater increase in plasma creatinine or
renal replacement therapy within the first 72 hours following
surgery. Plasma CyC and NGAL were not useful predictors of
acute kidney injury within the first 6 hours following surgery.
In contrast, both urinary CyC and NGAL were elevated in the
34 patients who later developed acute kidney injury,
compared to those with no injury. The urinary NGAL at the
time of ICU arrival and the urinary CyC level 6 hours after ICU
admission were most useful for predicting acute kidney
injury. A composite time point consisting of the maximum
urinary CyC achieved in the first 6 hours following surgery
outperformed all individual time points. Our study suggests
that urinary CyC and NGAL are superior to conventional and
novel plasma markers in the early diagnosis of acute kidney
injury following adult cardiac surgery.
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Acute kidney injury (AKI) is a common and serious
complication of cardiothoracic surgery;1 depending on the
definition of AKI used, it may occur in over 40% of adults,
with 1–5% requiring renal replacement therapy (RRT).2–9 In
cardiac surgery patients, postoperative increases of serum
creatinine of 20–25% from preoperative baselines are
associated with increased morbidity and mortality.6,10–12
The mortality associated with severe, RRT-requiring AKI
after cardiac surgery can be has high as 60%, depending on
the definition of the postoperative period and type of cardiac
surgery performed.2,3,5–7,9,13,14 It is clear that the risk of both
AKI and severe, RRT-requiring AKI is greatest in those with
preoperative renal dysfunction, particularly among those
undergoing more complex procedures.1,15–17 Despite a variety
of clinical tools to predict AKI and stratify its severity
following cardiothoracic surgery, there have been no
dramatic changes in AKI incidence, severity, or patient
outcomes in this high-risk setting, or in others.1,15,18–21
Unlike experimental models, in which primary or early
secondary prophylaxis for AKI has been successful with a
variety of agents, unsuccessful clinical trials of such therapies
have generally randomized a heterogeneous population of
patients with markedly elevated plasma creatinine values and
established AKI. Validation of one or more biomarkers that
are diagnostic in the early perioperative period would enrich
trials of early therapy of evolving AKI in this setting.
Similarly, if such a biomarker panel could also predict AKI
severity, and in particular whether RRT is likely required,
then accurate stratification of patients to receive pharma-
cotherapy or early RRT in randomized trials would be
possible.
Serum creatinine, the currently accepted ‘gold standard’ to
diagnose AKI, is a delayed and inadequate marker of acute
changes in renal function. In AKI, serum creatinine elevation
that reflects the development and severity of kidney damage
does not occur until days after renal tubular injury has
begun.14,22 In the setting of cardiac surgery, it is common
for the serum creatinine to decrease in the immediate
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postoperative period, even in those who go on to develop
severe AKI requiring RRT, further diminishing the diagnostic
utility of serum creatinine elevation to detect AKI in the early
postoperative period.23 Similarly, detection of postoperative
oliguria is not a sensitive or specific tool to diagnose
postoperative AKI or predict its potential reversibility or
severity. Numerous past attempts to treat AKI have failed,
conceivably because they were started too late and in the
presence of established acute tubular necrosis (ATN).24 The
failure to identify one or more reliable markers of early renal
injury in serum or urine to serve as a ‘renal troponin’ is one
of the major impediments to progress in AKI therapy, in
comparison to the improvement in the outcome of acute
coronary syndromes or chronic kidney disease in recent
years.25–28
International societies have made several aspects of AKI
research top priorities, including discovery and validation of
AKI biomarkers for diagnosis prior to the rise in serum
creatinine.29 Recent years have seen several studies investigat-
ing novel serum and urine AKI biomarkers in a variety of
settings. Coca et al.30 recently performed a systematic
literature review evaluating 31 studies that assessed 21 unique
serum and urine biomarkers of AKI. Although they note that
several of these biomarkers performed well at a variety of
tasks, including diagnosing early AKI (serum cystatin C
(CyC), urinary neutrophil gelatinase-associated lipocalin
(NGAL) and interleukin-18) as well as predicting mortality
(urine kidney injury molecule-1 and interleukin-18), they
concluded that these markers need validation in larger
studies.
Recently, serum CyC was shown to detect AKI earlier than
serum creatinine in critically ill patients.27,31 CyC is a
nonglycosylated 13 kDa basic protein that is a member of
the cystatin superfamily of cysteine protease inhibitors. It is
produced by all nucleated cells, unaffected by muscle mass
(unlike creatinine). It was long thought that its production
rate was similarly unaltered by inflammatory conditions,32–34
although recent data demonstrate that in the absence of
chronic kidney disease, serum CyC may be associated
with inflammatory biomarkers in an elderly, ambulatory
population.35 CyC is excreted by glomerular filtration, then
undergoes essentially complete tubular reabsorption and
catabolism (without secretion), so that it is not normally
found in urine in significant amounts.27,36,37 This is in
agreement with recent findings that demonstrate that
elevated levels of urinary CyC may reflect tubular dysfunction
and tubulointerstitial disease.38
NGAL, a 25 kDa member of the lipocalin family, is
markedly upregulated in the early postischemic mouse and
rat kidney.39 Serum and urine NGAL levels are elevated
earlier than serum creatinine in the setting of delayed graft
function following kidney transplantation40 and percuta-
neous coronary intervention.41 Mishra et al.42 demonstrated
in children undergoing cardiac surgery that NGAL concen-
trations increase in serum and urine within 2 h post-
cardiopulmonary bypass, preceding the serum creatinine
elevation, in those who go on to develop AKI. There was no
increase in children with stable perioperative renal func-
tion.42,43 Wagener et al.23 similarly found that urinary NGAL
is useful in the early diagnosis of AKI in adults after cardiac
surgery, although the test performance was significantly
inferior in this population to the seminal pediatric study
(area under the curve (AUC) under the receiver operating
characteristic (ROC) curve for urinary NGAL was 0.8 at 18 h,
but only 0.68 at 1 h and 0.74 at 3 h postoperation, whereas it
was 0.998 at 2 h and 1.0 at 4 h in the Mishra study). Taken
together with the fact that only limited numbers of cardiac
surgery patients (adult or pediatric) have been studied, it is
clear that the role of NGAL in the diagnosis of perioperative
AKI requires further investigation.
RESULTS
Patient characteristics
A total of 262 patients were screened for study enrollment. Of
them 162 were excluded because they met one or more
exclusion criteria and 49 declined to participate. In total 81
subjects consented for the study, of whom 73 subjects
completed the protocol; the most common reason for failure
to complete the protocol despite informed consent was an
unanticipated preoperative cardiac catheterization within
24 h of surgery. Of these 73 individuals, 1 died in the
operating room, had no postoperative data, and was excluded
from the analysis. The clinical characteristics of the remain-
ing 72 subjects are listed in Table 1.
Study end points and patient outcomes
Of the 72 study subjects, 34 (47.2%, 95% confidence interval
(CI, 35.3, 59.3%)) of patients developed postoperative AKI
(the primary study end point) as defined by a peak increase
of plasma creatinine of greater than or equal to 25% (from
preoperative baseline) (Figure 1a) or need for RRT (Table 2)
within 3 days of the surgery. The mean preoperative plasma
creatinine for all 72 subjects was 1.25 mg/100 ml (median¼
1.08 mg/100 ml), consistent with their mean preoperative
Modification of Diet in Renal Disease-estimated glomerular
filtration rate (eGFR) of 70.6 ml/min per 1.73 m2 body
surface area. Baseline plasma creatinine (mg/100 ml; median
(interquartile range)) was 1.05 (0.90–1.50) in the group that
did not develop AKI (n¼ 38), not significantly different than
the AKI group (1.14 (0.92–1.24), n¼ 34, P¼ 0.86). There was
also no significant difference in baseline eGFR values between
the two groups (P¼ 0.87; Table 1).
The peak plasma creatinine (mg/100 ml) within 72 h
postoperatively (‘72 h Max’) was significantly greater, by
definition, in the AKI group than in the group that did not
develop AKI (1.65 (1.28–2.22) vs 1.15 (1.06–1.48), respec-
tively; Po0.001). Furthermore, peak plasma creatinine
increased with increasing AKI severity (Po0.001): no AKI
(1.15, 1.06–1.48), AKI without RRT (1.56, 1.26–1.84), and
RRT (2.84, 1.42–5.41). Of the 34 AKI subjects, 13 (38.2%)
had a X50% increase in their plasma creatinine without
receiving RRT. Of these 34 patients, 7 (20.6%) went on to
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require RRT, all initiated with continuous venovenous
hemodialysis. Clinical features, indications, and timing of
initiation of the RRT cases are in listed in Table 2. Four
(11.8%) of these AKI subjects died during their postoperative
hospital course, with three of the four deaths in those
requiring RRT; none of the cohort without AKI died during
their hospitalization (P¼ 0.045). Similarly, there were
significantly longer intensive care unit (ICU) stays and
duration of hospitalization in the AKI group (Table 1). Finally,
the AKI group had a trend towards longer mean cardiopul-
monary bypass pump (CPB) times than those without AKI
(220.4 vs 180.2 min, respectively; P¼ 0.065; Table 1).
Plasma cystatin C
Similar to plasma creatinine (Figure 1a), plasma CyC
decreased from preoperative values at the initial post-
operative time points (Figure 1b). There was no difference
between the preoperative baseline plasma CyC values of those
with and without AKI (P¼ 0.92; Table 3), or in a three-group
comparison (no AKI, AKI without RRT, RRT; P¼ 0.55).
There was no significant difference between the maximum
plasma CyC values of those with and without AKI in the early
postoperative period (post-CPB, ICU arrival, and 6 h ICU
time points: the ‘early composite’ period), although there was
a trend toward higher values in the AKI group (P¼ 0.071;
Table 3). This composite time point represents a period
approximately 24 h prior to the diagnosis of AKI. The trend
toward higher plasma CyC values in the AKI group
continued subsequently, so that there was a significantly
higher 72 h peak value for plasma CyC in those who
developed AKI compared to those without AKI (Table 3),
and evidence for an overall difference in plasma CyC change
over time (interaction Po0.01 from repeated-measures
analysis of variance, ANOVA).
We generated ROC curves for plasma CyC to detect AKI, a
plasma creatinine elevation of at least 25% or RRT, at varied
time points and combinations of time points throughout the
protocol. The results are mentioned in Table 4a. Plasma CyC
was not a useful early predictor of the development of AKI.
None of the time points examined demonstrated significantly
better diagnostic ability than what would be expected by
chance, as indicated by the 95% CIs all including 0.5. The
Table 1 | Clinical characteristics of subjects (n=72)
Variable No AKI (n=38) AKI (n=34) P-value
Preoperative factors
Age 65.0 (51.0–73.0) 64.5 (50.0–76.0) NS
Female sex 11 (28.9) 10 (29.4) NS
Race
Caucasian 26 (68.4) 26 (76.5) NS
Afr. Am. 7 (18.4) 5 (14.7)
Hispanic 4 (10.6) 2 (5.9)
Other 1 (2.6) 1 (2.9)
Baseline eGFR (MDRD) ml/min per 1.73 m2 70.1±4.5 71.2±4.8 NS
Cleveland Clinic score 3 (2–6) 4 (3–6) NS
Wijeysundera JAMA score 2 (1–3) 2 (1–3) NS
Diabetes mellitus 8 (21.1) 9 (26.5) NS
Ejection fraction 52.0 (30.0–60.0) 50.0 (31.5–58.9) NS
(n=31) (n=27)
Surgery type
CABG alone 7 (18.4) 6 (17.6) NS
Valve alone 10 (26.3) 5 (14.7)
CABG+valve 15 (39.5) 10 (29.4)
CABG+other 1 (2.6) 2 (5.9)
Valve+other 2 (5.3) 7 (20.6)
Other 3 (7.9) 4 (11.8)
Reoperation 11 (28.9) 9 (26.5) NS
Operative factors
Cardiopulmonary bypass time (min) 180.2±10.8 220.4±18.4 NS (0.065)
Off-pump surgeries 4 (10.5) 4 (11.8) NS
Cross-clamp time (minutes) 144.2±8.6 158.6±8.8 NS
No cross-clamp surgeries 9 (23.7) 7 (20.6) NS
Outcomes
ICU days 4 (3–5) 5 (3.75–10) 0.038
Postoperative hospital days 7 (6–9) 10 (7.75–19) 0.003
Mortality in hospital 0 (0.0) 4 (11.8) 0.045
Data are expressed as mean±s.e., median (25–75%), or number (percentage).
AKI, acute kidney injury; Afr. Am., African American; CABG, coronary artery bypass graft surgery; eGFR, estimated glomerular filtration rate; NS, not significant (P40.05); MDRD,
Modification of Diet in Renal Disease.
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ROC curve for the maximum value of plasma CyC during the
early composite period can be found in Figure 2.
Urinary cystatin C
Urinary CyC values are reported as the urinary concentration
indexed to urinary creatinine excretion (subsequently
referred to simply as urinary CyC and expressed in mg
cystatin per gram of creatinine (mg/g)). At preoperative
baseline, there was minimal urinary CyC excretion in the
entire cohort.
There was no difference in the preoperative baseline
urinary CyC concentrations between groups, whether looking
at the cohort dichotomously (no AKI vs AKI, P¼ 0.42;
Table 3) or in three groups (no AKI, AKI without RRT, and
RRT; P¼ 0.49; Figure 3). The urinary concentration of CyC
increased in all individuals following cardiac surgery, but the
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Figure 1 | Plasma creatinine, cystatin C, and NGAL over time. (a) Plasma creatinine over time. This figure displays the plasma
creatinine (mean±1 s.e.) during the perioperative period in all subjects with and without acute kidney injury (AKI). Note that the plasma
creatinine generally decreased below baseline values at the first two postoperative time points; this early postoperative decrease in plasma
creatinine was similarly seen in both groups. The diagnosis of AKI (X25% increase from preoperative baseline) could generally not be made
until at least the first postoperative day (diagnosed at day 1 or later in 23 of 34 patients). Similarly, note that the mean plasma creatinine
does not increase by 50% in AKI subjects until day 2. (b) Plasma cystatin C (CyC) over time. The mean preoperative value was 1.47 mg/l in
those with no AKI and 1.46 mg/l in those with AKI. Similar to the plasma creatinine (a), plasma CyC generally decreased below baseline
values in the immediate postoperative period; this early postoperative decrease in plasma CyC was seen in both groups but persisted in
those with no AKI. A 25% increase in mean CyC does not occur until postoperative day 2, and a 50% increase on day 3 in those with
AKI. Mean values are displayed in the figure with error bars representing ±1 s.e. (c) Plasma neutrophil gelatinase-associated lipocalin
(NGAL) over time. This graph depicts the plasma NGAL (mean±s.e.) at preoperative and several postoperative time points. There
is no significant difference in the preoperative baseline values between those who develop AKI and those with no AKI (P¼ 0.83).
The NGAL changes similarly in both groups throughout the early postoperative period (P¼ 0.93 for interaction, P¼ 0.79 for group
main effect).
Table 2 | RRT cases, indications, and outcomes
Age/sex/race
Plasma
creatinine at RRT
start (mg/100 ml)
Hours in ICU
postoperation
prior to RRT Indications Outcome
40/M/AA 5.4 25.3 Refractory hyperkalemia (6 mEq/l), oliguria Currently receiving outpatient RRT
74/M/Cauc. 3.48 51.2 Anuria, elevated creatinine, shock Off RRT prior to hospital discharge
78/F/Cauc. 1.42 21.6 Volume overload, hypoxia, oliguria, shock Died POD no. 28
68/M/Cauc. 3.79 26.8 Lactic acidosis, oliguria, shock, elevated
creatinine
Discharged on RRT—lost to follow
up after 4 months.
62/M/AA 1.74 5.3 Anuria, shock, volume overload, acidosis Off RRT after 2.5 months
31/F/Hisp. 1.28 3.0 Lactic acidosis, anuria, shock Died POD no. 8
62/M/Cauc. 2.80 81.0 Volume overload, shock, hypoxia Died POD no. 10
AA, African American; Cauc., Caucasian; F, female; Hisp., Hispanic; ICU, intensive care unit; M, male; POD, postoperative day; RRT, renal replacement therapy.
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magnitude of these changes over time differed significantly by
group (interaction Po0.01 from repeated-measures ANO-
VA). Subsequent post hoc comparisons indicated that as early
as the first postoperative time point (while the patient is still
in the OR), those who did not develop AKI increased their
urinary CyC concentration by almost eightfold, but those
who developed AKI increased on average by over 147-fold
(P¼ 0.007). As further evidence of these differences, patients
who developed AKI had both higher early composite
postoperative maximum and 3-day maximum urinary CyC
concentrations when compared to those without AKI
(Po0.001 for both; Table 3). Figure 3 shows the early
perioperative urinary CyC concentrations for the three
groups (No AKI, AKI without RRT, and RRT). As with the
two group comparison, changes over time differed signifi-
cantly across groups (interaction Po0.01 from repeated-
measures ANOVA). Although the most dramatic increase was
seen in the RRT group, urinary CyC concentrations increased
significantly according to the severity of AKI (no AKIo AKI
without RRTo RRT) at each of the early postoperative time
points (Po0.01).
Exploratory subgroup analysis found that although there
was very little difference in their baseline values (P¼ 0.32),
women (n¼ 21) had significantly higher early postoperative
Table 3 | Plasma and urinary cystatin and NGAL values in the perioperative period
Variable No AKI (n=38) AKI (n=34) P-value
Plasma CyC (mg/l)
Baseline 1.23 (1.05–1.52) 1.36 (1.03–1.61) NS
(0.71–3.75) (0.71–5.10)
Maximum 72 h 1.31 (1.11–1.73) 1.90 (1.31–2.55) 0.019
(0.64–3.75) (0.78–8.39)
Maximum early composite 1.17 (0.96–1.36) 1.29 (1.06–1.87) NS
(0.64–3.31) (0.78–3.90)
Urine CyC/urine creatinine (mg/g)
Baseline 0.05 (0.03–0.07) 0.06 (0.04–0.09) NS
(0.01–0.30) (0.001–1.01)
Maximum 72 h 0.29 (0.10–0.78) 1.30 (0.54–3.52) o0.001
(0.02–5.06) (0.12–12.92)
Maximum early composite 0.18 (0.09–0.46) 0.92 (0.23–1.76) o0.001
(0.02–5.06) (0.06–10.64)
Plasma NGAL (ng/ml)
Baseline 104.2 (63.9–225.1) 116.5 (57.9–193.6) NS
(7.9–698.9) (10.0–588.7)
Maximum 72 h 392.0 (251.5–599.9) 393.9 (300.7–731.8) NS
(17.7–2137.8) (12.5–1663.7)
Maximum early composite 371.2 (195.5–597.3) 378.8 (210.3–731.8) NS
(13.9–1810.5) (12.5–1663.7)
Urine NGAL/urine creatinine (ng/mg)
Baseline 3.2 (1.7–8.0) 3.0 (2.3–7.2) NS
(0.2–119.3) (0.6–196.7)
Maximum 72 h 157.3 (29.8–1068.8) 1136.1 (243.6–4226.8) 0.002
(9.7–6029.7) (17.9–25725.3)
Maximum early composite 147.2 (24.2–1068.8) 1136.1 (176.6–4226.8) 0.006
(1.6–6029.7) (3.0–24289.6)
Data are expressed as median (25–75%) (min–max).
AKI, acute kidney injury; Cr, creatinine; CyC, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin; NS, not significant (P40.05).
Maximum 72 h is the maximum value during the first 72 postoperative hours.
Maximum early composite is the maximum value during the first 6 postoperative hours (time points post-CPB, ICU, and 6 h ICU).
Table 4 | AUC for ROC curves of CyC and NGAL for predicting
AKI
AUC (95% CI)
(a) Plasma cystatin C
Post-CPB value 0.631 (0.485–0.777)
ICU arrival value 0.617 (0.484–0.750)
6 h ICU value 0.627 (0.495–0.760)
Maximum early composite (post-CPB/ICU per 6 h) 0.624 (0.493–0.754)
Urinary cystatin C
Post-CPB value 0.709 (0.573–0.845)
ICU arrival value 0.693 (0.567–0.818)
6 h ICU value 0.724 (0.601–0.846)
Maximum early composite (post-CPB/ICU per 6 h) 0.734 (0.617–0.850)
(b) Plasma NGAL
Post-CPB value 0.448 (0.294–0.602)
ICU arrival value 0.526 (0.388–0.664)
6 h ICU value 0.463 (0.324–0.602)
Maximum early composite (post-CPB/ICU per 6 h) 0.536 (0.399–0.672)
Urinary NGAL
Post-CPB value 0.607 (0.461–0.753)
ICU arrival value 0.705 (0.581–0.829)
6 h ICU value 0.704 (0.579–0.829)
Maximum early composite (post-CPB/ICU/6 h) 0.691 (0.567–0.815)
AUC, area under the curve; ICU, intensive care unit; CPB, cardiopulmonary bypass
pump; NGAL, neutrophil gelatinase-associated lipocalin.
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maximum urinary CyC concentrations compared to men
(P¼ 0.037). In addition, although there was no difference in
their preoperative values (P¼ 0.52), those who had off-pump
surgery (n¼ 8) had lower early composite postoperative
maximum urinary CyC concentrations than those who were
on CPB (0.107 (0.0681–0.392) vs 0.415 (0.12–1.41), respec-
tively; P¼ 0.049). Among those who had CPB, there was
a significant correlation between duration of CPB and
maximum urinary CyC excretion during the early post-
operative period (r¼ 0.30, P¼ 0.018).
ROC curves were constructed to test the ability of urinary
CyC to predict AKI. The results are given in Table 4a. Urinary
CyC at the 6 h ICU time point (AUC¼ 0.724, 95% CI (0.601–
0.846); P¼ 0.002) and the maximum early composite value
(AUC¼ 0.734, 95% CI (0.617–0.850); Po0.001; Figure 2) were
excellent predictors of AKI after cardiac surgery. A sensitivity
and specificity analysis for selected values of urinary CyC as a
predictor of AKI development was performed. Positive and
negative likelihood ratios were calculated (Table 5a).
To examine whether urinary CyC had unique predictive
ability beyond that provided by more standard risk factors
(that is, age, race, gender, diabetes, CPB time, baseline eGFR,
and baseline creatinine), logistic regression models were fit
with and without urinary cystatin and the area under the
ROC curves from these models was compared. The early
composite maximum was an independent predictor of AKI
development with an AUC of 0.725 compared to an AUC of
0.604 (P¼ 0.036). These data suggest that urinary CyC can
aid in the early detection of AKI following cardiac surgery.
Fractional excretion of sodium
When comparing the fractional excretion of sodium (FENA)
over time between those with and without AKI, there was no
significant difference between these groups at baseline or any
subsequent time point (interaction P¼ 0.51 and group main
effect P¼ 0.71 from repeated-measures ANOVA). Nor was
there an effect present when comparing the maximum or
minimum value over the first 3 postoperative days or over the
early composite postoperative period (data not shown).
Fractional excretion of urea
Similar to the FENA, there was no significant difference in
the baseline fractional excretion of urea (FE Urea) values
when comparing those with and without AKI (P¼ 0.26).
There was evidence for a difference in FE Urea levels over
time (interaction P¼ 0.067 and group main effect Po0.01
from repeated-measures ANOVA, data not shown). As a
result, a statistically significant difference in the minimum
value over the 3-day postoperative period (Po0.001) and the
minimum over the early composite period (P¼ 0.004) was
found, with those developing AKI having lower FE Urea
values. From post hoc comparisons at individual time points,
a significant difference between groups did not appear
until the 6 h ICU time point and persisted through day 3
(P¼ 0.041 at 6 h ICU to P¼ 0.002 at day 2). Although the
magnitude of the difference varied, those with AKI main-
tained consistently lower FE Urea values. A similar effect was
seen when comparing the three groups; there was a negative
correlation between the minimum FE Urea values and
severity of AKI (no AKI4AKI without RRT4RRT; Po0.01).
Plasma NGAL
There was no significant difference in the baseline plasma
NGAL values of those with and without AKI (P¼ 0.83) or in
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for the maximum early composite (maximum values from the first
6 postoperative hours) for all four biomarkers of acute kidney
injury. The AUC is greatest for urine cystatin C (CyC, 0.734)
followed by urine neutrophil gelatinase-associated lipocalin
(NGAL, 0.691) followed by plasma CyC (0.624) and then plasma
NGAL (0.536). However, these differences in the AUCs did not
reach statistical significance (P¼ 0.11). Urine CyC (Po0.001) and
urine NGAL (P¼ 0.006) at this early postoperative composite time
point were the only two biomarkers to significantly predict the
future development of acute kidney injury (AKI).
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the three-group comparison (P¼ 0.26). Unlike plasma
creatinine and CyC, plasma NGAL increased from preopera-
tive values in the early postoperative period regardless of AKI
outcome (interaction P¼ 0.93 and group main effect
P¼ 0.79 from repeated-measures ANOVA; Figure 1c). As
such, there was no difference between the maximum plasma
NGAL value in those with and without AKI over the
early composite (P¼ 0.60) or 3-day postoperative period
(P¼ 0.54). A similar lack of effect was found when
comparing across three groups (no AKI, AKI without RRT,
and RRT). ROC curves were generated for plasma NGAL to
detect AKI at varied time points and combination of time
points throughout the protocol (Table 4b). Plasma NGAL
was not a useful early marker of the development of AKI; at
best the AUC (95% CI) was 0.536 (0.399–0.672); P¼NS
at the early composite time point (Figure 2).
Urinary NGAL
Urinary NGAL values are reported, as previously published,42
as the urinary concentration indexed to creatinine excretion;
subsequently referred to as urinary NGAL. There was mini-
mal difference in the preoperative baseline NGAL concentra-
tions between those with and without AKI (P¼ 0.71; Table 3)
and between the three groups (no AKI, AKI without RRT,
and RRT; P¼ 0.41; Figure 4). Urinary NGAL increased in all
patients postoperatively, and there was evidence for a
difference between the no AKI and AKI groups in urinary
NGAL levels over time (interaction P¼ 0.068 and group
Table 5 | Performance of urinary CyC and NGAL to predict AKI
Cutoff value Sensitivity (95% CI) Specificity (95% CI) LR+ LR
(a) Urine CyC/urine creatinine (mg/g)
Post-CPB value 0.108 88.9 (70.8, 97.6) 43.3 (25.5, 62.6) 1.57 0.26
0.350 63.0 (42.4, 80.6) 66.7 (47.2, 82.7) 1.89 0.56
0.466 59.3 (38.8, 77.6) 73.3 (54.1, 87.7) 2.22 0.56
ICU arrival value 0.108 75.8 (57.7, 88.9) 47.2 (30.4, 64.5) 1.44 0.51
0.350 57.6 (39.2, 74.5) 72.2 (54.8, 85.8) 2.07 0.59
0.466 51.5 (33.5, 69.2) 80.6 (64.0, 91.8) 2.65 0.60
6 h ICU value 0.108 45.2 (27.3, 64.0) 83.8 (68.0, 93.8) 2.78 0.65
0.350 19.4 (7.5, 37.5) 97.3 (85.8, 99.9) 7.16 0.83
0.466 12.9 (3.6, 29.8) 97.3 (85.8, 99.9) 4.77 0.90
Maximum early composite (post-CPB/ICU per 6 h ICU) 0.108 93.9 (79.8, 99.3) 39.5 (24.0, 56.6) 1.55 0.15
0.350 66.7 (48.2, 82.0) 63.2 (46.0, 78.2) 1.81 0.53
0.466 66.7 (48.2, 82.0) 76.3 (59.8, 88.6) 2.81 0.44
(b) Urine NGAL/urine creatinine (ng/mg)
Post-CPB value 300 57.1 (37.2, 75.5) 56.3 (37.7, 73.6) 1.31 0.76
572 53.6 (33.9, 72.5) 65.6 (46.8, 81.4) 1.56 0.71
1200 39.3 (21.5, 59.4) 81.3 (63.6, 92.8) 2.10 0.75
ICU arrival value 300 66.7 (48.2, 82.0) 62.2 (44.8, 77.5) 1.76 0.54
572 60.6 (42.1, 77.1) 73.0 (55.9, 86.2) 2.24 0.54
1200 45.5 (28.1, 63.6) 78.4 (61.8, 90.2) 2.10 0.70
6 h ICU value 300 34.4 (18.6, 53.2) 86.1 (70.5, 95.3) 2.48 0.76
572 25.0 (11.5, 43.4) 97.2 (85.5, 99.9) 9.00 0.77
1200 18.8 (7.2, 36.4) 97.2 (85.5, 99.9) 6.75 0.84
Maximum early composite (post CPB/ICU/6 h ICU) 300 66.7 (48.2, 82.0) 57.9 (40.8, 73.7) 1.58 0.58
572 60.6 (42.1, 77.1) 68.4 (51.3, 82.5) 1.92 0.58
1200 48.5 (30.8, 66.5) 78.9 (62.7, 90.4) 2.30 0.65
CPB, cardiopulmonary bypass pump; ICU, intensive care unit; LR+, positive likelihood ratio; LR, negative likelihood ratio.
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Figure 4 | Urinary NGAL excretion over time. Similar to urine
cystatin concentrations (Figure 3), there is no difference between
the preoperative urinary neutrophil gelatinase-associated
lipocalin (NGAL) values across the three groups (P¼ 0.41). We see
an early increase in urinary NGAL that correlates with severity of
acute kidney injury (AKI) beginning at the intensive care unit (ICU)
time point. Values displayed in the figure are mean±s.e.
*Pp0.001, **Pp0.01 for three-group comparison.
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main effect Po0.01 from repeated-measures ANOVA). On
the basis of post hoc comparisons, significant differences were
found at the ICU arrival (P¼ 0.003), 6 h ICU (P¼ 0.004),
and day 1 (Po0.001) time points. Patients with AKI had
higher early composite (P¼ 0.006; Table 3) as well as 3-day
maximum urinary NGAL values (P¼ 0.002). Figure 4 shows
the early perioperative urinary NGAL concentrations across
the three groups (no AKI, AKI without RRT, and RRT). As
with the two-group comparison, there were differences
between groups over time (interaction P¼ 0.085 and group
main effect Po0.01 from repeated-measures ANOVA).
Although the most dramatic increase was seen in the RRT
group, there was a significant positive correlation between
urinary NGAL concentrations and the severity of AKI (no AKI
o AKI without RRT o RRT) at each of the early postopera-
tive time points (Po0.01) except for post-CPB (P¼ 0.068).
ROC curves were constructed to test the ability of urinary
NGAL to predict AKI development (Table 4b). Urinary
NGAL at the ICU arrival had the best performance
(AUC¼ 0.705, 95% CI (0.581–0.829); P¼ 0.003) although
not significantly better than the other individual time points
or the maximum early composite (AUC¼ 0.691, 95% CI
(0.567–0.815); P¼ 0.006; Figure 2). A sensitivity and
specificity analysis for urinary NGAL as a test for predicting
AKI development was performed. Similar to CyC, several
cutoff values were chosen and positive and negative like-
lihood ratios were determined (Table 5b).
Comparison of cystatin C and NGAL
The area under the ROC curves for the plasma and urine of
the two markers were compared. The early composite
maximum was used in all cases. No statistically significant
differences between the two markers were found (serum
P¼ 0.36, urine P¼ 0.51), although in each case CyC had
better predictive ability than NGAL. In addition, whether the
combination of the urine levels of the two markers was better
than either on its own was tested but did not yield a
significant improvement (P¼ 0.69). However, the limited
power available for these comparisons is acknowledged.
DISCUSSION
We hypothesized that concentrations of CyC in plasma
(a GFR marker) and urine (a proximal tubular injury marker)
would be early biomarkers of AKI following cardiac surgery,
preceding significant plasma creatinine increases. Plasma
CyC levels increase before creatinine levels in patients with
progressive chronic kidney disease.32,34 Similarly, emerging
data suggest that plasma CyC levels increase 1–2 days before
plasma creatinine in patients developing AKI in a variety of
settings,32 including radiocontrast nephropathy,44 and AKI in
critically ill patients.31,45 This phenomenon is explained by
the shorter plasma elimination half-life of CyC.46 To date,
thyroid dysfunction, corticosteroids, and inflammatory
biomarkers have been shown to alter serum CyC levels
independent of GFR;47 although there is some dispute in the
literature as to whether serum CyC concentration is altered
by body/muscle mass and inflammation.35,48,49 Limited
data suggest that appearance of increased concentrations of
CyC in urine may be a sensitive marker of renal tubular
injury,27,36,37 and may correlate with severity of AKI.27
In this study, we have shown that renal dysfunction
following cardiac surgery is associated with increased urinary
and plasma CyC concentrations. Similar to creatinine,
plasma CyC initially decreases in the early postoperative
period. Across the entire cohort, the plasma creatinine
decreased by an average of 8% at the post-CPB time point,
when the plasma CyC decreased by an average of 22%. This
dramatic decrease in both markers makes their clinical utility
to define AKI difficult to interpret in the hours immediately
following cardiac surgery. Plasma NGAL, a marker of
inflammation, appears to increase in all individuals following
surgery and does not appear to suffer from this dilutional
effect. Of course, as both CyC and creatinine can serve as
markers for GFR, it is not surprising that both values
subsequently rebound and increase more significantly in
those who go on to develop AKI. However, contrary to the
current literature in other forms of AKI, plasma CyC did not
appear to be a useful AKI biomarker in the early post-
operative period following cardiac surgery. Although the
AUC values for plasma CyC were all above 0.60, none of the
promising early time points had a value greater than 0.70,
and all of the 95% CIs included 0.50, indicating that it was
not significantly better than what would be expected
by chance (Table 4a). This is in part because the mean
plasma CyC for those who go on to develop AKI, depicted in
Figure 1b, does not increase 25% (from preoperative
baseline) until day 2, and does not increase 50% until day
3. Although several studies have reported that plasma CyC
increases earlier than plasma creatinine in the setting of
AKI,31 none of these were conducted in the setting of cardiac
surgery. In summary, based on these findings, plasma CyC
does not serve as a useful early AKI biomarker in this setting,
perhaps confounded by the effects of perioperative hemo-
dilution on plasma biomarker concentrations.
Similar to CyC, plasma NGAL did not show much
promise as an AKI biomarker in the early postoperative
period. All of the AUC values were less than 0.60, and as with
plasma CyC they all had 95% CIs that included 0.50 (Table 4b).
This was relatively surprising, as the Mishra study found that
plasma NGAL could detect AKI before plasma creatinine
elevation following pediatric cardiac surgery (AUC under the
ROC curve was 0.998 at 2 h post-CPB).42 Several possibilities
exist for the discrepancy between our data and the earlier
published report. Our samples were immediately frozen at
80 1C and analyzed in the same lab as the Mishra paper.
However, we chose to measure NGAL in plasma rather than
serum (as in prior publications). Although unpublished data
from their lab demonstrate no significant difference between
plasma and serum levels of NGAL, the difference in our
approach is acknowledged. We also used a different definition
of AKI than the Mishra study, which used a 50% serum
creatinine increment cutoff. More importantly, our adult
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patient population differed significantly from the children of
the Mishra study. The similarity of our urine NGAL findings
to those of Wagener et al., who also studied adult cardiac
surgery patients, is supportive of this hypothesis (of note,
Wagener et al. did not measure serum NGAL, only urine). It
remains to be determined whether inflammation-induced
increases in serum NGAL following cardiac bypass in adults
with numerous comorbidities (our study subjects were
chronically ill individuals, on average 61.3 years old, 23.6%
were diabetics, 27.8% were having their second (or more)
cardiac surgery) result in inferior performance of this marker
in this population compared to children. Processes of care
also differ between the adult and pediatric cardiac surgery
populations; for example, although we excluded patients who
received radiocontrast within 24 h of surgery, such proce-
dures are not typically performed in the preoperative period
before pediatric cardiac surgery, and may have had some
effects in the adult studies. Operative factors may also have
played a major role in this phenomenon. It should be noted
that the mean (±s.e.) CPB time for those who had bypass
was 199±11 min. This is a 2- to 3-fold increase from the
pump times reported in previous NGAL literature, which is
another plausible explanation for the marked increased in
plasma NGAL seen in all of our study subjects, irrespective of
AKI development. Preexisting vascular and renal disease may
also explain the poorer performance of urinary NGAL as an
early AKI biomarker in the adults studied by Wagener and
our cohort, compared to the pediatric population. Of course,
the growing literature studying AKI biomarkers in both
pediatric and adult cardiac surgery patients will continue to
expand our knowledge regarding the impact of such clinical
variables on test performance in validation studies.
Similar to urine NGAL, this study showed that AKI
following cardiac surgery is associated with an early post-
operative increase in urinary CyC excretion. Urinary CyC
concentrations have not been widely studied; values are
customarily indexed to the urine creatinine. We have clearly
demonstrated that an early and persistent increase of urinary
CyC after cardiac surgery correlates with the development
and severity of AKI. The latter finding is similar to previous
work by Herget-Rosenthal et al.27, who demonstrated that
increased urinary CyC excretion in the setting of AKI
correlated with the requirement for RRT. Our data suggest
that urinary CyC concentrations have utility beyond the
ability to provide an earlier diagnosis of AKI. The observed
correlation with AKI severity offers the potential to stratify
cases of ATN, clearly separating those with established ATN
bound for RRT from those with lesser tubular injury or
reversible, prerenal azotemia. This point is underscored by
the comparatively poor performance in this regard of two
standard urine chemistry indices in our study. Whereas the
FENA was simply not useful to predict AKI or stratify
severity, the FE Urea was actually misleading in our cohort.
Specifically, the FE Urea values were significantly lower at
several of the early postoperative time points in those who
required RRT compared to the rest of the group (with a
negative correlation between FE Urea values and AKI
severity); yet this same RRT group had extremely elevated
urinary CyC concentrations at these same early time points.
This increase in urinary CyC suggested the presence of
tubular injury, whereas the low FE Urea values suggested that
these AKI cases had a ‘prerenal’ etiology. Further larger
studies that include other AKI biomarkers will be of great
interest as we seek further explanation of this phenomenon.
Our study has some limitations. It is a single-center study
of limited size, and thus should be confirmed in a larger
multicenter study. We did not measure GFR directly, but
plasma concentrations of two GFR markers (creatinine and
CyC) exhibited similar patterns over time (Figures 1a and b).
We defined AKI as a 25% increase in plasma creatinine
within 72 h of surgery. Although some previous studies have
used a 50% increase as their definition, emerging data suggest
that smaller changes have significant clinical impact includ-
ing increased ICU and hospital length of stay as well as
increased morbidity and mortality.6,10 Regardless, urinary
CyC concentrations were significantly increased at the first
postoperative time point in those who would develop
AKI compared to those who did not, although plasma
creatinine did not peak until day 2 (a full 48 h after ICU
arrival; Figure 1a), and AKI could not be diagnosed by
plasma creatinine elevation of any degree before 24–28 h post-
operatively. We anticipate that a larger trial could more
definitively establish a cutoff value for urinary CyC that is
predictive of AKI. Although we could not precisely distinguish
prerenal azotemia from ATN in all cases of AKI, our data
suggest that marked elevation of urinary CyC (but not FE
Urea or FENA) in the early postoperative period is likely
diagnostic of AKI caused by severe, dialysis-requiring ATN.
In summary, our study found that increased urinary CyC
excretion is a useful early biomarker of AKI in adults
following cardiac surgery, and the extent of excretion of this
marker correlates with the severity of AKI. Urinary NGAL is a
similarly useful early biomarker of AKI in this setting,
although it does not perform as well as in some previously
published studies. Urinary CyC should be a component of
urinary AKI marker panels assembled and tested to diagnose
and evaluate AKI.
MATERIALS AND METHODS
Patients and methods
We screened all patients admitted to the University of Chicago
Cardiac Surgery service for elective surgery between August 2005
and August 2007. All patients eligible for enrollment were
approached. Exclusion criteria included (1) age o18 years; (2)
preexisting end-stage kidney disease receiving RRT or post-renal
transplantation; (3) emergent cardiac surgery; (4) unstable renal
function (change in serum creatinine of X0.2 mg per 100 ml within
the past month, or oliguria o400 ml per day); (5) use of radio-
contrastp24 h prior to the surgery; (6) preexisting hypothyroidism
with a change in thyroid hormone dose in the past 2 weeks; and (7)
patients receiving corticosteroid therapy with a change in their dose
within the past 2 weeks. Written informed consent was obtained
from all patients at the time of their enrollment. The study was
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approved by the institutional review board of the University of
Chicago.
All patients were prospectively followed from the time of their
enrollment. Blood and urine samples were collected simultaneously
at predetermined time points; at the time of study enrollment, on
the day of the surgery preoperatively (immediately post-anesthesia
induction), postoperatively (after coming off CPB), upon arrival in
the ICU, 6 h after arriving in the ICU, daily for the next 7 days (days
1–7), then weekly for the next 3 weeks (days 14, 21, and 28) and at
the time of hospital discharge. Patients were considered to have
completed the study at the time of their hospital discharge.
Blood samples were centrifuged at 3600 r.p.m. for 15 min and the
plasma was stored at 80 1C. Urine samples were collected and
some unspun urine was stored at 80 1C. In addition, as previously
described,42 urine was centrifuged at 2000 r.p.m. for 5 min and the
supernatants were aliquoted and stored at 80 1C. Sample analysis
was batched and deferred until the time of study completion
(hospital discharge).
Preoperative patient characteristics, significant intraoperative risk
factors and peri- and postoperative complications were recorded on
all patients. All therapeutic and clinical care decisions were made by
the primary cardiac surgery service. In addition, the decision to
initiate RRT or make other renal interventions was made by the
primary service and the Nephrology Consult Service attending
without involvement of the study investigators. A variety of clinical
scoring systems1,21 were used to assess the preoperative risk for AKI.
The primary end point was the development of AKI, defined as a
25% or greater increase in the plasma creatinine from the
preoperative baseline or the need for RRT within the first 3
postoperative days. Secondary end points included a 50% or greater
increase in plasma creatinine from preoperative levels, in-hospital
mortality, and length of ICU and hospital stays. Other variables
recorded included age, sex, ethnicity, CPB time, cross-clamp time,
past medical history (hypertension, congestive heart failure,
diabetes, and so on), previous cardiothoracic surgery, preoperative
creatinine clearances estimated by both Cockcroft and Gault and
Modification of Diet in Renal Disease equations,50,51 serial plasma
and urine creatinine, sodium and urea nitrogen.
Cystatin C enzyme-linked immunosorbent assay
The levels of CyC in plasma and urine were quantitated using an
enzyme-linked immunosorbent assay (Human Cystatin C ELISA
kits: BioVendor LLC, Candler, NC, USA). Briefly, kit-supplied plates
were purchased precoated with polyclonal anti-human CyC-specific
antibody. The plates were loaded with 100 ml of sample (urine or
plasma at appropriate dilution) or standards (CyC concentration
ranging from 200 to 10,000 ng/ml), and run according to the
manufacturer’s instructions. Assays were run in duplicate or
triplicate, and read on a Bio-Tek Synergy HT plate-reader (BioTek
Instruments, Winooski, VT, USA). The mean intraassay coefficient
of variation was 3.9% for plasma CyC and 5.1% for urine CyC for
batched samples prepared on the same day. The mean interassay
coefficient of variation was 10.3%. Laboratory investigators were
blinded to the sample source and clinical outcomes. Plasma and
urine creatinine were measured by the alkaline picrate reaction,
plasma and urine urea nitrogen were measured by the urease
method, and plasma and urine sodium were measured with an
ion-selective electrode (Beckman Unicell DxC 600, Beckman
Coulter, Fullerton, CA, USA). FENA and FE urea were calcu-
lated as follows: FENA%¼ 100 (UrineNaPlasmaCr/PNaUCr);FE
urea%¼ 100 (UreaPlasmaCr/BUNUCr).
Enzyme-linked immunosorbent assay for NGAL
Previously published protocols for the detection of NGAL from
neutrophils52 were modified for this project. This protocol itself has
been previously published.42 Briefly, microtiter plates were coated
overnight at 4 1C with a mouse monoclonal antibody raised against
human NGAL (HYB211-05; AntibodyShop, Gentofte, Denmark).
All subsequent steps were undertaken at room temperature. Plates
were blocked with buffer containing 1% bovine serum albumin,
coated with 100 ml of samples (urine or plasma) or standards
(NGAL concentrations ranging from 1 to 1000mg/l), and incubated
with a biotinylated monoclonal antibody against human
NGAL (HYB211-01B; AntibodyShop) followed by avidin-conju-
gated horseradish peroxidase (Dako, Carpinteria, CA, USA).
Tetramethylbenzidine substrate (BD Biosciences, San Jose, CA,
USA) was added for color development, which was read after 30 min
at 450 nm with a microplate reader (Benchmark Plus; Bio-Rad,
Hercules, CA, USA). All measurements were made in triplicate in a
blinded fashion.
Statistics
Results are expressed as mean±s.e. or median and interquartile
range (25–75%). SigmaStat 3.5 (Systat Software Inc., San Jose, CA,
USA) or Stata version 9 (StataCorp, College Station, TX, USA) were
used for analyses. For continuous variables, a t-test or a
Mann–Whitney U-test, as appropriate, was performed for compar-
ison between two groups. When comparing more than two groups,
ANOVA or the Kruskal–Wallis test was used. Spearman’s rank
correlation coefficients were utilized for further assessment of the
correlation between marker levels and severity of AKI. For an overall
comparison of change over time between groups, a repeated-
measures ANOVA was performed with particular interest in the
interaction between group and time. A w2 or Fisher’s exact test was
used for analysis of categorical variables. A P-value of o0.05 was
considered statistically significant. ROC curves were generated for
the various markers at the postoperative, ICU admit and 6 h ICU
time points, as well as the maximum value at these three time points
(referred to as the early composite time point). The area under the
ROC curve (AUC) was calculated as a measure of the utility of the
CyC and NGAL concentrations as early markers of AKI. An area
under the curve of 0.5 indicates a marker with accuracy no better
than expected by chance, whereas a value of 1.0 signifies a biomarker
with perfect diagnostic accuracy. The AUCs were compared using
methods described by DeLong et al.53 In addition, logistic regression
was employed to further explore the unique predictive ability of
these markers.
DISCLOSURE
P Devarajan—licensing agreements with Abbott Diagnostics
and Biosite Inc. for developing NGAL as a biomarker of acute renal
failure.
ACKNOWLEDGMENTS
Part of this work was presented at the American Society of
Nephrology meeting in San Francisco, CA on 3 and 4 November
2007. This project was supported by the following grants to
Dr Murray: NIH 1K23GM00713-01A1 (from NIGMS); National Kidney
Foundation of Illinois Research Grant for the Young Investigator;
University of Chicago General Clinical Research Center Award
(PHS MO1RR000055); Dr Koyner was supported by NIH 2 T32
DK007510; and Dr Worcester was supported by NIH NIDDK
PO1 56788.
1068 Kidney International (2008) 74, 1059–1069
o r i g i n a l a r t i c l e JL Koyner et al.: Urinary CyC as an early biomarker of AKI
REFERENCES
1. Wijeysundera DN, Karkouti K, Dupuis JY et al. Derivation and validation of
a simplified predictive index for renal replacement therapy after cardiac
surgery. JAMA 2007; 297: 1801–1809.
2. Abel R, Buckley M, Austen W et al. Etiology, incidence and prognosis of
renal failure following cardiac operations. Results of a prospective
analysis of 500 consecutive patients. J Thorac Cardiovasc Surg 1976; 71:
323–333.
3. Andersson L, Ekroth R, Bratteby L et al. Acute renal failure after coronary
surgery: a study of incidence and risk factors in 2009 consecutive
patients. Thorac Cardiovasc Surg 1993; 41: 237–241.
4. Chertow G, Levy E, Hammermeister K et al. Independent association
between acute renal failure and mortality following cardiac surgery.
Am J Med 1998; 104: 343–348.
5. Conlon P, Strafford-Smith M, WD W et al. Acute renal failure following
cardiac surgery. Nephrol Dial Transplant 1999; 14: 1158–1162.
6. MoraMangano C, Diamondstone L, Ramsey J et al. Renal dysfunction after
myocardial revascularization: risk factors, adverse outcomes, and hospital
resource utilization. Ann Intern Med 1998; 128: 194–203.
7. Ostermann M, Taube D, Morgan C et al. Acute renal failure following
cardiopulmonary bypass: a changing picture. Intensive Care Med 2000; 26:
565–571.
8. Tuttle K, Worrall N, Dahlstrom L et al. Predictors of ARF after cardiac
surgical procedures. Am J Kidney Dis 2003; 41: 76–83.
9. Zanardo G, Michielon P, Paccagnella A et al. Acute renal failure in the
patient undergoing cardiac operation: prevalence, mortality rate, and
main risk factors. J Thorac Cardiovasc Surg 1994; 107: 1489–1495.
10. Lassnigg A, Schmidlin D, Mouhieddine M et al. Minimal changes of serum
creatinine predict prognosis in patients after cardiothoracic surgery: a
prospective cohort study. J Am Soc Nephrol 2004; 15: 1597–1605.
11. Loef B, Epema A, Smilde T et al. Immediate postoperative renal function
deterioration in cardiac surgical patients predicts in-hospital mortality
and long-term survival. J Am Soc Nephrol 2005; 16: 195–200.
12. Ryckwaert F, Boccara G, Frappier J et al. Incidence, risk factors, and
prognosis of a moderate increase in plasma creatinine after cardiac
surgery. Crit Care Med 2002; 30: 1495–1498.
13. Bove T, Calabro MG, Landoni G et al. The incidence and risk of acute renal
failure after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18: 442–445.
14. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac
surgery. Clin J Am Soc Neprol 2006; 1: 19–32.
15. Mehta RH, Grab JD, O’Brien SM et al. Bedside tool for predicting the risk
of postoperative dialysis in patients undergoing cardiac surgery.
Circulation 2006; 114: 2208–2216; quiz 2208.
16. Roques F, Nashef SA, Michel P et al. Risk factors and outcome in European
cardiac surgery: analysis of the EuroSCORE multinational database of
19,030 patients. Eur J Cardiothorac Surg 1999; 15: 816–822; discussion
822–3.
17. Thakar C, Liangos O, Yared J-P et al. Predicting acute renal failure after
cardiac surgery: validation and redefinition of a risk stratification
algorithm. Hemodial Int 2003; 7: 143–147.
18. Eriksen B, Hoff K, Solberg S. Prediction of acute renal failure after cardiac
surgery: retrospective cross-validation of a clinical algorithm. Nephrol Dial
Transplant 2003; 18: 77–81.
19. Fortescue E, Bates D, Chertow G. Predicting acute renal failure after
coronary bypass surgery: cross-validation of two risk-stratification
algorithms. Kidney Int 2000; 57: 2594–2602.
20. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of
risk for evaluating the results of surgery in acquired adult heart disease.
Circulation 1989; 79(6 Part 2): I3–I12.
21. Thakar CV, Arrigain S, Worley S et al. A clinical score to predict acute renal
failure after cardiac surgery. J Am Soc Nephrol 2005; 16: 162–168.
22. Murray P, Le Gall J, Dos Reis Miranda D et al. Physiologic endpoints
(efficacy) for acute renal failure studies. Curr Opin Crit Care 2002; 8:
519–525.
23. Wagener G, Jan M, Kim M et al. Association between increases in urinary
neutrophil gelatinase-associated lipocalin and acute renal dysfunction
after adult cardiac surgery. Anesthesiology 2006; 105: 485–491.
24. Tang I, Murray P. Prevention of perioperative ARF: what works? Best Prac
Res Clin Anesthesiol 2004; 18: 91–111.
25. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of
ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199–2210.
26. Dagher PC, Herget-Rosenthal S, Ruehm SG et al. Newly developed
techniques to study and diagnose acute renal failure.[see comment].
J Am Soc Nephrol 2003; 14: 2188–2198.
27. Herget-Rosenthal S, Poppen D, Husing J et al. Prognostic value of tubular
proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin
Chem 2004; 50: 522–558.
28. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54: 1817–1831.
29. Nephrology TASo. The American Society of Nephrology Renal Research
Report. J Am Soc Nephrol 2005; 16: 1886–1903.
30. Coca SG, Yalavarthy R, Concato J et al. Biomarkers for the diagnosis and
risk stratification of acute kidney injury: a systematic review. Kidney Int
2007; 19: 19.
31. Herget-Rosenthal S, Marggraf G, Husing J et al. Early detection of acute
renal failure by serum cystatin C. Kidney Int 2004; 66: 1115–1122.
32. Laterza O, Price C, Scott M. Cystatin C: an improved estimator of
glomerular filtration rate? Clin Chem 2002; 48: 699–707.
33. Massey D. Commentary: clinical diagnostic use of cystain C. J Clin Lab
Analysis 2004; 18: 55–60.
34. Newman DJ, Thakkar H, Edwards RG et al. Serum cystatin C measured by
automated immunoassay: a more sensitive marker of changes in GFR
than serum creatinine. Kidney Int 1995; 47: 312–318.
35. Keller CR, Odden MC, Fried LF et al. Kidney function and markers of
inflammation in elderly persons without chronic kidney disease: the
health, aging, and body composition study. Kidney Int 2007; 71: 239–244.
36. Herget-Rosenthal S, Feldkamp T, Volbracht L et al. Measurement of
urinary cystain C by particle-enhanced nephelometric immunoassay:
precision, interferences, stability, and reference range. Ann Clin Biochem
2004; 41(Part 2): 111–118.
37. Uchida K, Cotoh A. Measurement of cystatin-C and creatinine in urine.
Clin Chim Acta 2002; 323: 121–128.
38. Herget-Rosenthal S, van Wijk JA, Brocker-Preuss M et al. Increased urinary
cystatin C reflects structural and functional renal tubular impairment
independent of glomerular filtration rate. Clin Biochem 2007; 40: 946–951.
39. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-
associated lipocalin as a novel early urinary biomarker for ischemic renal
injury. J Am Soc Nephrol 2003; 14: 2534–2543.
40. Parikh CR, Jani A, Mishra J et al. Urine NGAL and IL-18 are predictive
biomarkers for delayed graft function following kidney transplantation.
Am J Transplant 2006; 6: 1639–1645.
41. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E et al. Neutrophil-
gelatinase-associated lipocalin and renal function after percutaneous
coronary interventions. Am J Nephrol 2006; 26: 287–292.
42. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated
lipocalin (NGAL) as a biomarker for acute renal injury after cardiac
surgery. Lancet 2005; 365: 1231–1238.
43. Parikh CR, Mishra J, Thiessen-Philbrook H et al. Urinary IL-18 is an
early predictive biomarker of acute kidney injury after cardiac surgery.
Kidney Int 2006; 70: 199–203.
44. Rickli H, Benou K, Ammann P et al. Time course of serial cystatin levels in
comparison with serum creatinine after application of radiocontrast
media. Clin Nephrol 2004; 61: 98–102.
45. Delanaye P, Lambermont B, Chapelle J et al. Plasmatic cystain C for the
estimation of glomerular filtration rate in intensive care units. Intensive
Care Med 2004; 30: 980–983.
46. Filler G, Bokenkamp A, Hofmann W et al. Cystatin C as a marker of
GFR—history, indications, and future research. Clin Biochem 2005; 38:
1–8.
47. Fricker M, Wiesli P, Brandle M et al. Impact of thyroid dysfunction on
serum cystatin C. Kidney Int 2003; 63: 1944–1947.
48. Macdonald J, Marcora S, Jibani M et al. GFR estimation using cystatin C is
not independent of body composition. Am J Kidney Dis 2006; 48:
712–719.
49. Shlipak MG. Cystatin C as a marker of glomerular filtration rate in chronic
kidney disease: influence of body composition. Nat Clin Pract Nephrol
2007; 3: 188–189.
50. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum
creatinine. Nephron 1976; 16: 31–41.
51. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Modification of Diet in Renal Disease Study Group. Ann Intern
Med 1999; 130: 461–470.
52. Kjeldsen L, Koch C, Arnljots K et al. Characterization of two ELISAs for
NGAL, a newly described lipocalin in human neutrophils. J Immunol
Methods 1996; 198: 155–164.
53. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics 1988; 44: 837–845.
Kidney International (2008) 74, 1059–1069 1069
JL Koyner et al.: Urinary CyC as an early biomarker of AKI o r i g i n a l a r t i c l e
